166 patents
Page 4 of 9
Utility
Heterodimeric Fc variants
2 Aug 22
Immunoglobulin compositions that simultaneously co-engage antigens, where one of the antigens is bound bivalently and the other antigen is bound monovalently.
Gregory Lazar, Gregory Moore
Filed: 13 Aug 19
Utility
ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS
21 Jul 22
The present invention is directed to novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a ICOS antibody fragment-Fc fusion protein.
Matthew J. Bernett, John R. Desjarlais, Gregory Moore, Suzanne Schubbert
Filed: 23 Dec 21
Utility
PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
5 Jul 22
The present invention is directed to novel PD-1 targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.
Matthew Bernett, John R. Desjarlais, Michael Hedvat, Suzanne Schubbert, Christine Bonzon, Rumana Rashid, Rajat Varma
Filed: 11 Oct 19
Utility
Bispecific and Monospecific Antibodies Using Novel ANTI-PD-1 Sequences
30 Jun 22
The present invention is directed to bispecific, heterodimeric checkpoint antibodies.
Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal, Umesh Muchhal
Filed: 16 Mar 22
Utility
IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS
23 Jun 22
The present invention is directed to novel IL15/IL15Rα heterodimeric Fc fusion proteins.
Matthew Bernett, Rumana Rashid, John Desjarlais, Rajat Varma, Christine Bonzon
Filed: 11 Mar 22
Utility
Methods of treating neurological diseases
21 Jun 22
The present disclosure is directed to a method of treating neurological disorder comprising peripheral administration to a patient in need thereof a DN-TNF polypeptide that inhibits the activity of soluble TNF- but not transmembrane TNF-α.
David Szymkowski, Malu Tansey, Lesley Probert
Filed: 10 Sep 13
Utility
Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseases
21 Jun 22
The present disclosure relates to immunoglobulins that bind FcγRIIb+ B cells and coengage CD19 on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins for the treatment of an IgG4-related disease.
Debra Zack, John H. Stone, Shiv Pillai, Paul Foster
Filed: 8 Jun 17
Utility
IL-12 heterodimeric Fc-fusion proteins
14 Jun 22
The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same.
Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Nargess Hassanzadeh-Kiabi, Rumana Rashid
Filed: 3 Oct 19
Utility
CTLA4-IG immunoadhesins
7 Jun 22
The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
Gregory A. Lazar, Matthew J. Bernett
Filed: 13 Nov 18
Utility
Heterodimeric antibodies that bind CD3 and CD38
7 Jun 22
The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Y. Chu, Rumana Rashid, Umesh Muchhal
Filed: 22 Oct 19
Utility
Heterodimeric Antibodies That Bind Somatostatin Receptor 2
26 May 22
The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind somatostatin receptor 2 (SSTR2)
Gregory Moore, Rumana Rashid, Sung-Hyung Lee, Paul Foster
Filed: 3 Dec 21
Utility
Heterodimeric Antibodies That Bind CD3 and Tumor Antigens
26 May 22
The present invention is directed to novel heterodimeric antibodies.
Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
Filed: 3 Dec 21
Utility
HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII
12 May 22
Provided herein are novel antibodies that bind TGFßRII and methods of making and using such antibodies.
John R. Desjarlais, Gregory Moore, Suzanne Schubbert, Alex Nisthal
Filed: 5 Nov 21
Utility
Bispecific Antibodies That Bind PD-L1 and CD28
5 May 22
Provided herein are novel αPD-L1 antibodies and methods of using such antibodies for the treatment of cancers.
John R. Desjarlais, Gregory Moore, Michael Hedvat, Juan Diaz, Veronica Gusti Zeng, Umesh S. Muchhal
Filed: 14 Oct 21
Utility
Engineered IL-2 Fc fusion proteins
3 May 22
The present invention provides IL-2-Fc fusion proteins comprising IL-2 variants.
Matthew Bernett, John Desjarlais, Rajat Varma, Rumana Rashid
Filed: 30 Nov 18
Utility
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
26 Apr 22
The present invention is directed to bispecific, heterodimeric checkpoint antibodies.
Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal, Umesh Muchhal
Filed: 8 Nov 18
Utility
Heterodimeric Antibodies That Bind Prostate Specific Membrane Antigen (Psma) and CD3
21 Apr 22
Provided herein are novel antigen binding domains and antibodies (e.g., heterodimeric antibodies) that bind Prostate Specific Membrane Antigen (PSMA).
John R. Desjarlais, Alex Nisthal, Michael Hedvat, Matthew Adam Dragovich
Filed: 14 May 21
Utility
ANTI-CD28 Compositions
21 Apr 22
Provided herein are novel anti-CD28×anti-B7H3 (also referred to as “αCD28×αB7H3”) heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers.
John R. Desjarlais, Gregory Moore, Michael Hedvat, Juan Diaz, Veronica Gusti Zeng
Filed: 21 Dec 21
Utility
Fc VARIANTS WITH ALTERED BINDING TO FcRn
14 Apr 22
The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
Aaron Keith Chamberlain, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Jost Vielmetter, Sean C. Yoder
Filed: 13 Dec 21
Utility
ANTI-CD28 Compositions
31 Mar 22
Provided herein are novel anti-CD28×anti-B7H3 (also referred to as “αCD28×αB7H3”) heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers.
John R. Desjarlais, Gregory Moore, Michael Hedvat, Juan Diaz, Veronica Gusti Zeng
Filed: 19 Aug 21